SYNTHESE VON CANTHARIDIN
European patent · EP3692044 · In force
Register entry
- Publication number
- EP3692044
- Application number
- EP18864069
- Kind
- European patent with effect for Switzerland and Liechtenstein
- Status
- In force
- Specification
- Granted
- Filed
- Oct 4, 2018
- Published
- Aug 12, 2020
- Granted
- Jan 24, 2024
- Protection ends at the latest
- Oct 3, 2038
- Next annual fee due
- Oct 31, 2027
- IPC classes
- C07D 495/22 (2006.01)C07D 493/18 (2006.01)
- Priority
- US 201762568004 P 04.10.2017
- PCT application
- PCT/US2018/054373 04.10.2018
- PCT publication
- WO2019/070980 11.04.2019
- Filing language
- English
- Source
- Swissreg
History
What the Federal Institute of Intellectual Property published about this title, newest first.
- Nov 1, 2026
Next annual fee due on
- Next annual fee due on
- 31.10.2026 → 31.10.2027
Published in Swissreg on 01.11.2026
- Nov 1, 2025
Next annual fee due on
- Next annual fee due on
- 31.10.2025 → 31.10.2026
Published in Swissreg on 01.11.2025
- Dec 4, 2024
Change
Published in Swissreg on 04.12.2024
- Nov 1, 2024
Next annual fee due on
- Next annual fee due on
- 31.10.2024 → 31.10.2025
Published in Swissreg on 01.11.2024
- Apr 3, 2024
Owner
- Owner
- Verrica Pharmaceuticals, Inc., 10 North High Street Suite 200, West Chester, PA 19380, USA → Verrica Pharmaceuticals Inc., 44 West Gay Street, Suite 400, West Chester, PA 19380, USA
Published in Swissreg on 03.04.2024
- Jan 24, 2024
Granted
Published in Swissreg on 24.01.2024
Parties
Inventor
Kalamazoo, MI 49009, US
Venice, CA 90291, US
Redwood City, CA 94065, US
Kalamazoo, MI 49009, US
Portage, MI 49024, US
The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.